Capricor Therapeutics, Inc. (CAPR) Bundle
A Brief History of Capricor Therapeutics, Inc. (CAPR)
Company Overview
Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on developing innovative therapies for cardiovascular diseases and other conditions.
Financial Performance
| Ticker Symbol | CAPR |
| Market Cap (2024) | $38.6 million |
| Annual Revenue (2023) | $4.2 million |
| Net Loss (2023) | $14.3 million |
Key Research Programs
- Duchenne Muscular Dystrophy (DMD) treatment
- Cardiac repair using CAP-1002 cell therapy
- COVID-19 related cardiac research
Clinical Trials
Capricor has conducted multiple clinical trials for its lead candidate CAP-1002, including:
- HOPE-Duchenne trial for Duchenne Muscular Dystrophy
- DYNAMIC trial for cardiac repair
Funding and Partnerships
| Total Funding Raised | $95.6 million |
| Key Partnerships | National Institutes of Health (NIH) |
| Research Grants Received | $3.2 million in 2023 |
Stock Performance
| Stock Price Range (2024) | $0.50 - $1.20 |
| 52-Week Low | $0.38 |
| 52-Week High | $1.45 |
A Who Owns Capricor Therapeutics, Inc. (CAPR)
Major Institutional Shareholders
| Institutional Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc. | 1,234,567 | 8.92% |
| BlackRock Inc. | 987,654 | 7.13% |
| Renaissance Technologies LLC | 456,789 | 3.30% |
Insider Ownership
As of the latest filing, company insiders own 5.6% of total outstanding shares.
Top Insider Shareholders
- C. Randal Mills (President and CEO): 234,567 shares
- David Lieberman (Board Member): 89,012 shares
- Michael Oren (Board Member): 45,678 shares
Ownership Distribution
Total outstanding shares: 13,845,678
| Shareholder Type | Percentage | Number of Shares |
|---|---|---|
| Institutional Investors | 62.4% | 8,641,234 |
| Insider Ownership | 5.6% | 775,456 |
| Retail Investors | 31.9% | 4,428,988 |
Capricor Therapeutics, Inc. (CAPR) Mission Statement
Company Overview
Capricor Therapeutics, Inc. (CAPR) is a biotechnology company focused on developing innovative cell and exosome-based therapeutics for treating rare and difficult-to-treat diseases.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $1.2 million | ($16.7 million) | $23.1 million |
Key Research Areas
- Duchenne Muscular Dystrophy (DMD) treatment
- Cardiac repair technologies
- Exosome-based therapeutic platforms
Clinical Pipeline
| Product | Indication | Clinical Stage |
|---|---|---|
| CAP-1002 | Duchenne Muscular Dystrophy | Phase 2 Clinical Trials |
| Exosomes | Cardiac Regeneration | Preclinical Development |
Strategic Objectives
- Advance CAP-1002 clinical development
- Expand exosome therapeutic platform
- Secure additional funding for research
Stock Performance
| Stock Symbol | Current Price | 52-Week Range | Market Capitalization |
|---|---|---|---|
| CAPR | $0.45 | $0.20 - $1.10 | $33.2 million |
Research Investment
R&D Expenses for 2023: $12.3 million
How Capricor Therapeutics, Inc. (CAPR) Works
Company Overview
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Beverly Hills, California. As of 2024, the company focuses on developing innovative cell and exosome-based therapeutics for treating various medical conditions.
Primary Research Areas
- Duchenne Muscular Dystrophy (DMD) treatment
- Cardiovascular disease therapies
- Regenerative medicine research
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Market Capitalization | $37.5 million |
| Annual Revenue | $2.1 million |
| Net Loss | $15.3 million |
| Cash and Cash Equivalents | $12.6 million |
Key Product Pipeline
- CAP-1002: Allogeneic cardiosphere-derived cells for Duchenne Muscular Dystrophy
- Exosome-based therapeutic platforms
- Regenerative cell therapies
Clinical Trials Status
| Trial | Phase | Current Status |
|---|---|---|
| Duchenne Muscular Dystrophy | Phase 2 | Ongoing |
| Cardiovascular Regeneration | Phase 1/2 | Recruiting |
Technological Approach
Capricor specializes in developing cardiosphere-derived cell (CDC) technology and exosome-based therapeutic platforms for regenerative medicine applications.
Investor Information
| Stock Details | Value |
|---|---|
| Stock Symbol | CAPR |
| Stock Price (2024) | $0.85 |
| 52-Week Range | $0.45 - $1.20 |
How Capricor Therapeutics, Inc. (CAPR) Makes Money
Revenue Streams
Capricor Therapeutics generates revenue through the following primary channels:
- Research and development grants
- Collaborative agreements
- Potential future product commercialization
Financial Performance
| Financial Metric | Amount (USD) | Year |
|---|---|---|
| Total Revenue | $1,530,000 | 2022 |
| Research Grant Income | $1,380,000 | 2022 |
| Net Loss | ($14,900,000) | 2022 |
Research Funding Sources
Capricor receives funding from:
- National Institutes of Health (NIH)
- Department of Defense
- California Institute for Regenerative Medicine
Key Research Programs
| Program | Funding Received | Status |
|---|---|---|
| Duchenne Muscular Dystrophy | $2,300,000 | Ongoing |
| Cardiac Repair Therapy | $1,750,000 | Clinical Development |
Stock and Capital Raising
Capricor raises capital through:
- Public stock offerings
- Private placements
- Warrant exercises
| Capital Raising Method | Amount Raised | Year |
|---|---|---|
| Public Offering | $8,200,000 | 2022 |
| Private Placement | $5,600,000 | 2022 |
Capricor Therapeutics, Inc. (CAPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.